Last edition
News about "TAE Life Sciences "
TAE Life Sciences’ latest research demonstrates the potential of next-generation BNCT to combine targeted radiation with immune activation for improved cancer treatment outcomes.
TAE Life Sciences | 11/04/2026 | By News Bureau
TAE Life Sciences and Stella Pharma to Commercialize BPA for BNCT Cancer Therapy
The collaboration objectives include extensive international cooperation in the development and commercialization of BNCT and BPA across the USA and Europe with clinical trials anticipated to begin in 2026.
TAE Life Sciences | 14/11/2024 | By Aishwarya | 680
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy